Small Molecules

20 Aug 2019 Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis
20 Aug 2019 Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
20 Aug 2019 Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
20 Aug 2019 Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-6219
19 Aug 2019 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
19 Aug 2019 On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer
19 Aug 2019 Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
19 Aug 2019 Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
17 Aug 2019 AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
17 Aug 2019 U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
16 Aug 2019 European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
16 Aug 2019 FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
15 Aug 2019 Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy
15 Aug 2019 FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
14 Aug 2019 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
14 Aug 2019 Emalex Biosciences Announces First Patient Enrolled in Phase 2b Clinical Study to Evaluate the Efficacy and Safety of Ecopipam Tablets for the Treatment of Pediatric Patients with Tourette Syndrome
14 Aug 2019 CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
13 Aug 2019 Terns Pharmaceuticals Announces Positive Interim Results From Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
13 Aug 2019 Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
13 Aug 2019 Janssen Announces European Commission Approval of Imbruvica® (ibrutinib) for Expanded Use in Two Indications
13 Aug 2019 Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors
13 Aug 2019 Basilea starts phase 1/2 study with derazantinib in urothelial cancer
12 Aug 2019 First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)
12 Aug 2019 Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis
12 Aug 2019 Janssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up